ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer

Breast Cancer Research and Treatment

Volumn 154, Issue 3, 2015, Pages 543-555

  Leyland Jones, Brian ^a   Gray, Kathryn P ^b   Abramovitz, Mark ^c   Bouzyk, Mark ^d   Young, Brandon ^a   Long, Bradley ^e   Kammler, Roswitha ^f   Dell’Orto, Patrizia ^g   Biasi, Maria Olivia ^g   Thürlimann, Beat ^h,i,j   Harvey, Vernon ^j,k,l   Neven, Patrick ^m   Arnould, Laurent ⁿ   Maibach, Rudolf ^f   Price, Karen N ^o   Coates, Alan S ^j,p   Goldhirsch, Aron ^g,j   Gelber, Richard D ^o   Pagani, Olivia ^j,q   Viale, Giuseppe ^r   Rae, James M ^s   Regan, Meredith M ^b   more..

^a Avera Health   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c VM Institute of Research   (Canada)

^d AKESOgen Inc   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f International Breast Cancer Study Group Coordinating Center   (Switzerland)

^g EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^h Breast Cancer   (Switzerland)

ⁱ SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^j International Breast Cancer Study Group   (Switzerland)

^k AUCKLAND CITY HOSPITAL   (New Zealand)

^l Australian New Zealand Breast Cancer Trials Group   (Australia)

^m UNIVERSITY OF LEUVEN   (Belgium)

ⁿ Georges Francois Leclerc Center   (France)

^o FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^p UNIVERSITY OF SYDNEY   (Australia)

^q ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^r UNIVERSITY OF MILAN   (Italy)

^s UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

more..

Author keywords

ESR1; ESR2; Letrozole; Polymorphism; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; LETROZOLE; TAMOXIFEN; ANTINEOPLASTIC AGENT; ESR2 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA, HUMAN; NITRILE; TRIAZOLE DERIVATIVE;

ADVERSE OUTCOME; ALLELE; ARTICLE; BONE DENSITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RISK; CONTROLLED STUDY; DNA ISOLATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; EARLY CANCER; ESR1 GENE; ESR2 GENE; ESTROGEN ACTIVITY; FEMALE; FRACTURE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HOMOZYGOSITY; HOT FLUSH; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MONOTHERAPY; NIGHT SWEAT; OSTEOPOROSIS; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RISK REDUCTION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CHEMICALLY INDUCED; CLINICAL TRIAL; EARLY CANCER DIAGNOSIS; GENETICS; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DOUBLE-BLIND METHOD; EARLY DETECTION OF CANCER; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HOT FLASHES; HUMANS; MIDDLE AGED; NITRILES; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTMENOPAUSE; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES;

EID: 84948381614     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3634-6     Document Type: Article

References (38)

1. Sowers MR, Wilson AL, Karvonen-Gutierrez CA, Kardia SR (2006) Sex steroid hormone pathway genes and health-related measures in women of 4 races/ethnicities: the Study of Women’s Health Across the Nation (SWAN). Am J Med 119(9 Suppl 1):S103–S110. doi:10.1016/j.amjmed.2006.07.012
2. Almeida S, Hutz MH (2008) Estrogen receptor 1 gene polymorphisms in premenopausal women: interaction between genotype and smoking on lipid levels. Bra J Med Biol Res 41(10):872–876
3. Hayes DF, Skaar TC, Rae JM, Henry NL, Nguyen AT, Stearns V, Li L, Philips S, Desta Z, Flockhart DA, Consortium on Breast Cancer P (2010) Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels: revised and updated results. Clin Pharmacol Ther 88(5):626–629. doi:10.1038/clpt.2010.143
4. Molvarec A, Nagy B, Kovacs M, Walentin S, Imreh E, Rigo J Jr, Szalay J, Fust G, Prohaszka Z, Karadi I (2007) Lipid, haemostatic and inflammatory variables in relation to the estrogen receptor alpha (ESR1) PvuII and XbaI gene polymorphisms. Clin Chim Acta 380(1–2):157–164. doi:10.1016/j.cca.2007.02.005
5. Ntukidem NI, Nguyen AT, Stearns V, Rehman M, Schott A, Skaar T, Jin Y, Blanche P, Li L, Lemler S, Hayden J, Krauss RM, Desta Z, Flockhart DA, Hayes DF, Consortium on Breast Cancer P (2008) Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen. Clin Pharmacol Ther 83(5):702–710. doi:10.1038/sj.clpt.6100343
6. Sowers MR, Symons JP, Jannausch ML, Chu J, Kardia SR (2006) Sex steroid hormone polymorphisms, high-density lipoprotein cholesterol, and apolipoprotein A-1 from the Study of Women’s Health Across the Nation (SWAN). Am J Med 119(9 Suppl 1):S61–S68. doi:10.1016/j.amjmed.2006.07.008
7. Crandall CJ, Sehl ME, Crawford SL, Gold EB, Habel LA, Butler LM, Sowers MR, Greendale GA, Sinsheimer JS (2009) Sex steroid metabolism polymorphisms and mammographic density in pre- and early perimenopausal women. Breast Cancer Res 11(4):R51. doi:10.1186/bcr2340
8. Onitilo AA, McCarty CA, Wilke RA, Glurich I, Engel JM, Flockhart DA, Nguyen A, Li L, Mi D, Skaar TC, Jin Y (2009) Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. Breast Cancer Res Treat 115(3):643–650. doi:10.1007/s10549-008-0264-2
9. Oger E, Lacut K, Mercier B, Le Gal G, Leroyer C, Pasquier E, Ferec C, Mottier D (2007) Estrogen receptor alpha polymorphism and venous thromboembolism in male and female: data from the EDITH study. Thromb Res 119(4):433–439. doi:10.1016/j.thromres.2006.05.002
10. Yaffe K, Lindquist K, Sen S, Cauley J, Ferrell R, Penninx B, Harris T, Li R, Cummings SR (2009) Estrogen receptor genotype and risk of cognitive impairment in elders: findings from the Health ABC study. Neurobiol Aging 30(4):607–614. doi:10.1016/j.neurobiolaging.2007.08.003
11. Boyapati SM, Shu XO, Ruan ZX, Cai Q, Smith JR, Wen W, Gao YT, Zheng W (2005) Polymorphisms in ER-alpha gene interact with estrogen receptor status in breast cancer survival. Clin Cancer Res 11(3):1093–1098
12. Dunning AM, Healey CS, Baynes C, Maia AT, Scollen S, Vega A, Rodriguez R, Barbosa-Morais NL, Ponder BA, Search, Low YL, Bingham S, Epic, Haiman CA, Le Marchand L, Mec, Broeks A, Schmidt MK, Abcs, Hopper J, Southey M, Abcfs, Beckmann MW, Fasching PA, Bbcc, Peto J, Johnson N, Bbcs, Bojesen SE, Nordestgaard B, Cgps, Milne RL, Benitez J, Cnio BCS, Hamann U, Ko Y, Genica, Schmutzler RK, Burwinkel B, Gc H, Schurmann P, Dork T, Habcs, Heikkinen T, Nevanlinna H, Hebcs, Lindblom A, Margolin S, Karbac, Mannermaa A, Kosma VM, Kbcs, Chen X, Spurdle A, kConFab, the AMG, Change-Claude J, Flesch-Janys D, Marie, Couch FJ, Olson JE, for M, Severi G, Baglietto L, Mccs, Borresen-Dale AL, Kristensen V, Nbcs, Hunter DJ, Hankinson SE, Nhs, Devilee P, Vreeswijk M, Origo, Lissowska J, Brinton L, Pbcs, Liu J, Hall P, Sasbac, Kang D, Yoo KY, Sebcs, Shen CY, Yu JC, Twbcs, Anton-Culver H, Ziogoas A, Ucibcs, Sigurdson A, Struewing J, Usrts, Easton DF, Garcia-Closas M, Humphreys MK, Morrison J, Pharoah PD, Pooley KA, Chenevix-Trench G, Bcac (2009) Association of ESR1 gene tagging SNPs with breast cancer risk. Hum Mol Genet 18 (6):1131–1139. doi:10.1093/hmg/ddn429
13. Gennari L, Merlotti D, De Paola V, Calabro A, Becherini L, Martini G, Nuti R (2005) Estrogen receptor gene polymorphisms and the genetics of osteoporosis: a HuGE review. Am J Epidemiol 161(4):307–320. doi:10.1093/aje/kwi055
14. Heilberg IP, Hernandez E, Alonzo E, Valera R, Ferreira LG, Gomes SA, Bellorin-Font E, Weisinger JR (2005) Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis. Ren Fail 27(2):155–161
15. Henry NL, Nguyen A, Azzouz F, Li L, Robarge J, Philips S, Cao D, Skaar TC, Rae JM, Storniolo AM, Flockhart DA, Hayes DF, Stearns V (2010) Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy. Br J Cancer 102(2):294–300. doi:10.1038/sj.bjc.6605460
16. Li N, Dong J, Hu Z, Shen H, Dai M (2010) Potentially functional polymorphisms in ESR1 and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 121(1):177–184. doi:10.1007/s10549-009-0532-9
17. Rapuri PB, Gallagher JC, Knezetic JA, Haynatzka V (2006) Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas 53(4):371–379. doi:10.1016/j.maturitas.2005.07.007
18. Breast International Group 1-98 Collaborative G, Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353(26):2747–2757. doi:10.1056/NEJMoa052258
19. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Lang I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J clin Oncol 25(5):486–492. doi:10.1200/JCO.2006.08.8617
20. Colleoni M, Giobbie-Hurder A, Regan MM, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Lang I, Smith I, Chirgwin J, Pienkowski T, Wardley A, Price KN, Gelber RD, Coates AS, Goldhirsch A (2011) Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J clin Oncol 29(9):1117–1124. doi:10.1200/JCO.2010.31.6455
21. BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thurlimann B, Paridaens R, Smith I, Mauriac L, Forbes J, Price KN, Regan MM, Gelber RD, Coates AS (2009) Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 361(8):766–776. doi:10.1056/NEJMoa0810818
22. Giobbie-Hurder A, Price KN, Gelber RD (2009) Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. Clinical Trials 6(3):272–286. doi:10.1177/1740774509105380
23. Rae JM, Regan MM, Thibert JN, Gersch C, Thomas D, Leyland-Jones B, Viale G, Pusztai L, Hayes DF, Skaar T, Van Poznak C (2013) Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. J Natl Cancer Inst 105(17):1332–1334. doi:10.1093/jnci/djt204
24. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of the NCIEWGoCD (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23(36):9067–9072. doi:10.1200/JCO.2004.01.0454
25. Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell’orto P, Biasi MO, Thurlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G, Breast International Group 1-98 Collaborative G (2012) CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 104(6):441–451. doi:10.1093/jnci/djs125
26. Cai Q, Shu XO, Jin F, Dai Q, Wen W, Cheng JR, Gao YT, Zheng W (2003) Genetic polymorphisms in the estrogen receptor alpha gene and risk of breast cancer: results from the Shanghai Breast Cancer Study. Cancer Epidemiol Biomarkers Prev 12(9):853–859
27. Sakoda LC, Blackston CR, Doherty JA, Ray RM, Lin MG, Gao DL, Stalsberg H, Feng Z, Thomas DB, Chen C (2011) Selected estrogen receptor 1 and androgen receptor gene polymorphisms in relation to risk of breast cancer and fibrocystic breast conditions among Chinese women. Cancer Epidemiol 35(1):48–55. doi:10.1016/j.canep.2010.08.005
28. Shin A, Kang D, Nishio H, Lee MJ, Park SK, Kim SU, Noh DY, Choe KJ, Ahn SH, Hirvonen A, Kim JH, Yoo KY (2003) Estrogen receptor alpha gene polymorphisms and breast cancer risk. Breast Cancer Res Treat 80(1):127–131
29. Wang J, Higuchi R, Modugno F, Li J, Umblas N, Lee J, Lui LY, Ziv E, Tice JA, Cummings SR, Rhees B (2007) Estrogen receptor alpha haplotypes and breast cancer risk in older Caucasian women. Breast Cancer Res Treat 106(2):273–280. doi:10.1007/s10549-007-9497-8
30. Iwasaki M, Hamada GS, Nishimoto IN, Netto MM, Motola J Jr, Laginha FM, Kasuga Y, Yokoyama S, Onuma H, Nishimura H, Kusama R, Kobayashi M, Ishihara J, Yamamoto S, Hanaoka T, Tsugane S (2009) Isoflavone, polymorphisms in estrogen receptor genes and breast cancer risk in case-control studies in Japanese, Japanese Brazilians and non-Japanese Brazilians. Cancer Sci 100(5):927–933. doi:10.1111/j.1349-7006.2009.01118.x
31. Li LW, Xu L (2012) Menopausal status modifies breast cancer risk associated with ESR1 PvuII and XbaI polymorphisms in Asian women: a HuGE review and meta-analysis. Asian Pac J Cancer Prev 13(10):5105–5111
32. Maguire P, Margolin S, Skoglund J, Sun XF, Gustafsson JA, Borresen-Dale AL, Lindblom A (2005) Estrogen receptor beta (ESR2) polymorphisms in familial and sporadic breast cancer. Breast Cancer Res Treat 94(2):145–152. doi:10.1007/s10549-005-7697-7
33. Yu KD, Rao NY, Chen AX, Fan L, Yang C, Shao ZM (2011) A systematic review of the relationship between polymorphic sites in the estrogen receptor-beta (ESR2) gene and breast cancer risk. Breast Cancer Res Treat 126(1):37–45. doi:10.1007/s10549-010-0891-2
34. Henry NL, Giles JT, Ang D, Mohan M, Dadabhoy D, Robarge J, Hayden J, Lemler S, Shahverdi K, Powers P, Li L, Flockhart D, Stearns V, Hayes DF, Storniolo AM, Clauw DJ (2008) Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 111(2):365–372. doi:10.1007/s10549-007-9774-6
35. Wang J, Lu K, Song Y, Xie L, Zhao S, Wang Y, Sun W, Liu L, Zhao H, Tang D, Ma W, Pan B, Xuan Q, Liu H, Zhang Q (2013) Indications of clinical and genetic predictors for aromatase inhibitors related musculoskeletal adverse events in Chinese Han women with breast cancer. PLoS ONE 8(7):e68798. doi:10.1371/journal.pone.0068798
36. Jin Y, Hayes DF, Li L, Robarge JD, Skaar TC, Philips S, Nguyen A, Schott A, Hayden J, Lemler S, Storniolo AM, Flockhart DA, Stearns V (2008) Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. J Clin Oncol 26(36):5849–5854. doi:10.1200/JCO.2008.16.8377
37. Ryan J, Canonico M, Carcaillon L, Carriere I, Scali J, Dartigues JF, Dufouil C, Ritchie K, Scarabin PY, Ancelin ML (2012) Hormone treatment, estrogen receptor polymorphisms and mortality: a prospective cohort study. PLoS ONE 7(3):e34112. doi:10.1371/journal.pone.0034112
38. Salmen T, Heikkinen AM, Mahonen A, Kroger H, Komulainen M, Saarikoski S, Honkanen R, Maenpaa PH (2000) Early postmenopausal bone loss is associated with PvuII estrogen receptor gene polymorphism in Finnish women: effect of hormone replacement therapy. J Bone Miner Res 15(2):315–321. doi:10.1359/jbmr.2000.15.2.315